Cargando…
Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
Autores principales: | Combe, Bernard, Balsa, Alejandro, Sarzi-Puttini, Piercarlo, Tony, Hans-Peter, de la Torre, Inmaculada, Rogai, Veronica, Durand, Frederick, Witt, Sarah, Zhong, Jinglin, Dougados, Maxime |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691861/ https://www.ncbi.nlm.nih.gov/pubmed/30842122 http://dx.doi.org/10.1136/annrheumdis-2018-214261 |
Ejemplares similares
-
Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials
por: Salvarani, Carlo, et al.
Publicado: (2021) -
Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome
por: Buskila, Dan, et al.
Publicado: (2006) -
What is the role of rheumatologists in the era of COVID-19?
por: Marotto, Daniela, et al.
Publicado: (2020) -
Primary and secondary autoimmune neutropenia
por: Capsoni, Franco, et al.
Publicado: (2005) -
Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report
por: Talotta, Rossella, et al.
Publicado: (2016)